Andreas Kalmes

Dr. Andreas Kalmes


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
AVAntonio Vallarola
Antonio Vallarola
FSFrancesca Sironi
Francesca Sironi
MTMassimo Tortarolo
Massimo Tortarolo
NGNoemi Gatto
Noemi Gatto
RGRoberta De Gioia
Roberta De Gioia
CBCaterina Bendotti
Caterina Bendotti
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor neuromuscular system leading to complete paralysis and premature death. The multifactorial nature of ALS that involves both cell-autonomous and non-cell-autonomous processes contributes to the lack of effective therapies, usually targeted to a single pathogenic mechanism. RNS60, an experimental drug containing oxygenated nanobubbles generated by modified Taylor-Couette-Poiseuille flow with elevated oxygen pressure, has shown anti-inflammatory and neuroprotective properties in different experimental paradigms. Since RNS60 interferes with multiple cellular mechanisms known to be involved in ALS pathology, we evaluated its effect in in vitro and in vivo models of ALS. Co-cultures of primary microglia/spinal neurons exposed to LPS and astrocytes/spinal neurons from SOD1G93A mice were used to examine the effect of RNS60 or normal saline (NS) on the selective motor neuron degeneration. Transgenic SOD1G93A mice were treated with RNS60 or NS (300 μl/mouse intraperitoneally every other day) starting at the disease onset and examined for disease progression as well as pathological and biochemical alterations. RNS60 protected motor neurons in in vitro paradigms and slowed the disease progression of C57BL/6-SOD1G93A mice through a significant protection of spinal motor neurons and neuromuscular junctions. This was mediated by the (i) activation of an antioxidant response and generation of an anti-inflammatory environment in the spinal cord; (ii) activation of the PI3K-Akt pro-survival pathway in the spinal cord and sciatic nerves; (iii) reduced demyelination of the sciatic nerves; and (iv) elevation of peripheral CD4+/Foxp3+ T regulatory cell numbers. RNS60 did not show the same effects in 129Sv-SOD1G93A mice, which are unable to activate a protective immune response. RNS60 demonstrated significant therapeutic efficacy in C57BL/6-SOD1G93A mice by virtue of its effects on multiple disease mechanisms in motor neurons, glial cells, and peripheral immune cells. These findings, together with the excellent clinical safety profile, make RNS60 a promising candidate for ALS therapy and support further studies to unravel its molecular mechanism of action. In addition, the differences in efficacy of RNS60 in SOD1G93A mice of different strains may be relevant for identifying potential markers to predict efficacy in clinical trials.

1 September 2025 in Stroke
Verified
Journal Article
Closed access
SGSupurna Ghosh
Supurna Ghosh
JDJordan S. Dubow
Jordan S. Dubow
JSJocelyn Sutherland
Jocelyn Sutherland
WSWendy Smith
Wendy Smith
DCDavid Chiu
David Chiu
RMRyan A. McTaggart
Ryan A. McTaggart
BACKGROUND: Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE (A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic. METHODS: This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale. RESULTS: The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3]; P <0.05). No statistically significant differences were observed in other efficacy end points, but a higher proportion of participants in the RNS60 1.0 mL/kg per hour group had reduced disability (modified Rankin Scale score of 0–2) and functional independence (Barthel Index ≥95) on Day 90. CONCLUSIONS: RNS60 was safe and well tolerated. The RNS60 1.0 mL/kg per hour reduced infarct growth after endovascular thrombectomy compared with placebo. This suggests a benefit warranting investigation in a larger, appropriately powered trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.

Verified
Journal Article
Open access
PDF file
MZMagdalena Zabielska-Kaczorowska
Magdalena Zabielska-Kaczorowska
BWBarbara Wierzbicka
Barbara Wierzbicka
AKAndreas Kalmes
Andreas Kalmes
ESEwa M. Slominska
Ewa M. Slominska
MYMagdi Yacoub
Magdi Yacoub
RSRyszard T. Smolenski
Ryszard T. Smolenski
RNS60 is a physically modified saline solution hypothesized to contain oxygen nanobubbles. It has been reported to reduce ischemia/reperfusion injury in a pig model of acute myocardial infarction. We investigated the effects of RNS60 during cardiac hypoxia in mice and as an additive to cardioplegic solution in rat hearts. ApoE−/−LDLr−/− mice were treated by intravenous injection of RNS60 or saline as a control while monitoring the ECG and post-hypoxic serum release of troponin T and creatine kinase activity. Hearts infused with Custodiol containing 10% RNS60 or saline as the control were subjected to 4 h of 4 °C preservation, followed by an assessment of myocardial metabolites, purine release, and mechanical function. RNS60 attenuated changes in the ECG STU area during hypoxia, while the troponin T concentration and creatine kinase activity were significantly higher in the serum of the controls. During reperfusion after 4 h of cold ischemia, the Custodiol/RNS60-treated hearts had about 30% lower LVEDP and better dp/dtmax and dp/dtmin together with a decreased release of purine catabolites vs. the controls. The myocardial ATP, total adenine nucleotides, and phosphocreatine concentrations were higher in the RNS60-treated hearts. This study indicates that RNS60 enhances cardioprotection in experimental myocardial hypoxia and under conditions of cardioplegic arrest. Improved cardiac energetics are involved in the protective effect, but complete elucidation of the mechanism requires further study.

4 June 2026 in Muscle & Nerve
Verified
Journal Article
Open access
DVDanny R. Vesevick
Danny R. Vesevick
SGSupurna Ghosh
Supurna Ghosh
AKAndreas Kalmes
Andreas Kalmes
POP. Hande Ozdinler
P. Hande Ozdinler
MGMukesh Gautam
Mukesh Gautam
Introduction: TDP‐43 pathology is broadly observed in the cerebral cortex of patients with amyotrophic lateral sclerosis (ALS). RNS60, an experimental treatment for acute ischemic stroke and ALS, enhanced mitochondrial biogenesis and function in other preclinical models. We investigated whether RNS60 improved mitochondrial stability and upper motor neuron (UMN) health in a TDP‐43 mouse model of ALS. Methods: prpTDP‐43 A315T ‐UeGFP mice, in which UMNs express green fluorescent protein (eGFP), and WT‐UeGFP mice were treated with RNS60 or placebo intraperitoneally every other day from post‐natal day (P) 30 until P90. Astrogliosis and microgliosis in brain and spinal cord were quantified by immunocytochemistry. Mitochondrial ultrastructure was studied via electron microscopy, and mitochondrial function was assessed using flow cytometry. Neuromuscular junction (NMJ) integrity was assessed in gastrocnemius, tibialis, and diaphragm muscles. Results: RNS60 treatment reduced defective mitochondria in UMNs (prpTDP‐43 A315T + vehicle: 53.2% ± 0.71%; prpTDP‐43 A315T + RNS60: 19.6% ± 1.4%, p = 0.0001) and spinal motor neurons (prpTDP‐43 A315T + vehicle: 70.1% ± 0.4.48%; prpTDP‐43 A315T + RNS60: 33.5% ± 4.43%, p = 0.001). It increased mitochondrial membrane polarization (prpTDP‐43 A315T ‐UeGFP + vehicle: 7184 ± 1689 mean intensity; prpTDP‐43 A315T ‐UeGFP+RNS60: 22120 ± 4818 mean intensity, p = 0.032), reduced the extent of astrogliosis and microgliosis in motor cortex and spinal cord, protected UMNs compared to placebo, and enhanced the proportion of intact NMJs in leg and diaphragm muscles (prpTDP‐43 A315T ‐UeGFP + vehicle: 29.6% ± 3.6%; prpTDP‐43 A315T ‐UeGFP + RNS60: 64.3% ± 4.4%, p = 0.0002). Discussion: These results suggest that RNS60 treatment promotes motor neuron health in ALS by protecting mitochondrial structure and function, preserving NMJ integrity, and reducing gliosis.

1 May 2026 in Stroke: Vascular and Interventional Neurology
Verified
Journal Article
Open access
SGSupurna Ghosh
Supurna Ghosh
JDJordan Dubow
Jordan Dubow
CFChristopher G. Favilla
Christopher G. Favilla
JSJocelyn Sutherland
Jocelyn Sutherland
AKAndreas Kalmes
Andreas Kalmes
RMRyan A. McTaggart
Ryan A. McTaggart
BACKGROUND: Adjunct therapies are needed for patients with acute ischemic stroke who fare poorly, despite standard-of-care endovascular thrombectomy (EVT). RESCUE (A Randomized, Blinded, Placebo-Controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) tested the cytoprotective experimental drug RNS60 in patients with acute ischemic stroke, adjunct to EVT with or without prior standard-of-care thrombolytic treatment. METHODS: RESCUE, a randomized, placebo-controlled, double-blind, phase 2 study, enrolled 83 participants eligible for EVT within 24 hours since last known well, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour. A post hoc analysis evaluated safety and efficacy in a subpopulation of 62 participants enrolled within 12 hours since last known well. Efficacy end points included modified Rankin Scale score, post-EVT infarct growth, National Institutes of Health Stroke Scale score, Barthel Index score, EuroQoL, and duration of hospitalization and discharge disposition. RESULTS: In this subpopulation, RNS60 1.0 mL/kg per hour was generally safe and well tolerated and reduced post-EVT infarct growth compared with placebo (least squares mean difference, 22.2; P =0.05). Of the participants treated with RNS60 1.0 mL/kg per hour, 72.2% achieved a 90-day modified Rankin Scale score of 0 to 2, and 72.2% achieved a Barthel Index score ≥95, compared with 36.8% (for both measures) of those receiving placebo, although the differences were not statistically significant ( P =0.09 for both modified Rankin Scale and Barthel Index scores). Consistent but smaller differences to placebo were seen in the RNS60 0.5 mL/kg per hour group, which suggests a dose-dependent effect of RNS60. Participants in the RNS60 1.0 mL/kg per hour group were also released earlier from the hospital than those in the placebo group (mean [SD]: 6.0 [5.10] days versus 10.8 [6.84] days; mean difference [SE], −4.8 [1.99]; P =0.02). Final infarct volumes at 48 hours post-EVT correlated with modified Rankin Scale scores at day 90 for RNS60 1.0 mL/kg per (Pearson r =0.65; P =0.005) and placebo ( r =0.65; P =0.007). CONCLUSIONS: Effects of RNS60 were favorable compared with placebo in the analyzed subpopulation, warranting further investigation in this population. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.